WallStreetZenWallStreetZen

NASDAQ: INVA
Innoviva Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

INVA past earnings growth

How has INVA's earnings growth performed historically?
Company
-10.42%
Industry
54.16%
Market
72.61%
INVA's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
INVA's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
INVA's earnings growth is slowing... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

INVA past revenue growth

How has INVA's revenue growth performed historically?
Company
-6.3%
Industry
144.63%
Market
17.55%
INVA's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
INVA's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
INVA's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

INVA earnings and revenue history

Current Revenue
$310.5M
Current Earnings
$179.7M
Current Profit Margin
57.9%

INVA Return on Equity

Current Company
29.7%
Current Industry
-63.5%
Current Market
188%
INVA's Return on Equity (29.7%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when INVA announces earnings.

INVA Return on Assets

Current Company
15.4%
Current Industry
2.9%
INVA is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

INVA Return on Capital Employed

Current Company
17.69%
Current Industry
19.5%
INVA's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

INVA vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
INVA$310.46M$248.96M$179.72M+3.53%-6.84%
SAVA$0.00-$95.69M-$97.22MN/AN/A
BCYC$26.98M-$169.40M-$180.66M+30.47%N/A
LQDA$17.49M-$69.65M-$78.50M+45.23%N/A
ABVX$5.02M-$129.52M-$160.59M-38.54%N/A
View Top Biotech Stocks

INVA earnings dates

Next earnings date
May 7, 2024

Innoviva Earnings & Revenue FAQ

What were INVA's earnings last quarter?

On Invalid Date, Innoviva (NASDAQ: INVA) reported Q4 2023 earnings per share (EPS) of $0.96, up 197.96% year over year. Total Innoviva earnings for the quarter were $61.53 million. In the same quarter last year, Innoviva's earnings per share (EPS) was -$0.98.

If you're new to stock investing, here's how to buy Innoviva stock.

What was INVA's earnings growth in the past year?

As of Q2 2024, Innoviva's earnings has grown -10.42% year over year. This is 64.58 percentage points lower than the US Biotechnology industry earnings growth rate of 54.16%. Innoviva's earnings in the past year totalled $179.72 million.

What is INVA's earnings date?

Innoviva's earnings date is Invalid Date. Add INVA to your watchlist to be reminded of INVA's next earnings announcement.

What was INVA's revenue last quarter?

On Invalid Date, Innoviva (NASDAQ: INVA) reported Q4 2023 revenue of $85.84 million up 30.45% year over year. In the same quarter last year, Innoviva's revenue was $65.80 million.

What was INVA's revenue growth in the past year?

As of Q2 2024, Innoviva's revenue has grown -6.3% year over year. This is 150.93 percentage points lower than the US Biotechnology industry revenue growth rate of 144.63%. Innoviva's revenue in the past year totalled $310.46 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.